To include your compound in the COVID-19 Resource Center, submit it here.

Genetic deletion of PD-1 enhances anti-tumor T cell therapy

Researchers from University College London (UCL) Cancer Institute and Cellectis S.A. (Euronext: ALCLS; NASDAQ: CLLS)

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE